2-{4-[4-(1-hydroxy-5,6,7,8-tetrahydro-naphthalen-2-yl)-piperidin-1-yl]-butyl}-isoindole-1,3-dione | 443131-31-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 2-{4-[4-(1-hydroxy-5,6,7,8-tetrahydro-naphthalen-2-yl)-piperidin-1-yl]-butyl}-isoindole-1,3-dione
• 英文别名: 2-[4-[4-(1-Hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)piperidin-1-yl]butyl]isoindole-1,3-dione
• CAS: 443131-31-5
• 化学式: C₂₇H₃₂N₂O₃
• 分子量: 432.563
• InChiKey: RQMQSADDHXQSEC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  32
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  60.8
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression
  申请人：——

  公开号：US20040077654A1

  公开（公告）日：2004-04-22

  The invention concerns Use of a compound of formula (I) or a physiologically acceptable salt, solvate or derivative thereof, in the manufacture of a medicament for the treatment of diseases ameliorated by LDL-r upregulation, to novel compounds and pharmaceutical compositions within the scope of formula (I).

  该发明涉及使用式(I)的化合物或其生理上可接受的盐、溶剂合物或衍生物，用于制造治疗通过LDL-r上调改善的疾病的药物，以及在式(I)范围内的新化合物和药物组合物。
• Aryl piperidine derivatives as inducers of ldl-receptor expression
  申请人：——

  公开号：US20040072865A1

  公开（公告）日：2004-04-15

  The invention concerns a compound of formula (I), wherein Ar 1 represents phenyl, naphthyl or phenyl fused by a C 3-8 cycloalkyl, where each group is substituted by a group —O-Z and optionally one to three further groups independently represented by R 1 ; Ar 2 represents phenyl or 5-6 membered heteroaromatic group, where each group is optionally substituted by one to four groups independently selected from halogen, C 1-4 alkyl and C 1-4 alkoxy; Ar 3 represents a phenyl or a 5-6 membered heteroaromatic group, where each group is optionally substituted by one to four groups independently selected from hydroxy, alkyl, C 1-4 alkoxy, C 2-4 alkenyl, C 2-4 alkenyloxy, C 1-4 perfluoroalkoxy, C 1-4 acylamino or an electron withdrawing group; A represents —C(H)—; E represents —C 1-6 alkylene-; X represents —CON(H or C 1-4 alkyl)- or —N(H or C 1-4 alkyl)CO—; Y represents a direct link, —N(H or C 1-4 alkyl)CO— or —CON(H or C 1-4 alkyl)-; Z represents a metabolically labile group; R 1 represents halogen, —S(C 1-4 alkyl), —O—(C 0-4 alkylene)-R 2 or —(C 0-4 alkylene)-R 2 , where each alkylene group may additionally incorporate an oxygen in the chain, with the proviso that there are at least two carbon atoms between any chain heteroatoms; R 2 represents: i) hydrogen, C 1-4 perfluoroalkyl, C 2-3 alkenyl, ii) phenyl, naphthyl, a 5- or 6-membered heteroaromatic group or 1,2,3,4-tetrahydronaphthyl, optionally substituted by one or two halogen, hydroxy, C 1-4 alkyl, C 1-4 alkoxy groups, iii) C 3-8 cycloalkyl, a 3-7 membered heterocycloalkyl, iv) amino, C 1-4 alkylamino or di-C 1-4 alkylamino, with the proviso that there are at least two carbon atoms between any chain heteroatoms; and physiologically acceptable salts, solvates and pharmaceutical compositions thereof and their use in treating disorders associated with elevated circulating levels of LDL-cholesterol.

  本发明涉及公式（I）的化合物，其中Ar1代表苯基，萘基或被C3-8环烷基融合的苯基，其中每个基都被-O-Z基取代，且可以有一到三个进一步独立表示为R1的基；Ar2代表苯基或5-6成员杂环芳基，其中每个基可选地被从卤素，C1-4烷基和C1-4烷氧基中独立选择的一到四个基取代；Ar3代表苯基或5-6成员杂环芳基，其中每个基可选地被从羟基，烷基，C1-4烷氧基，C2-4烯基，C2-4烯氧基，C1-4全氟烷氧基，C1-4酰胺基或电子提取基中独立选择的一到四个基取代；A代表-C（H）-；E代表-C1-6烷基-；X代表-CON（H或C1-4烷基）-或-N（H或C1-4烷基）CO-；Y代表直接连接，-N（H或C1-4烷基）CO-或-CON（H或C1-4烷基）-；Z代表代谢易变基团；R1代表卤素，-S（C1-4烷基），-O-（C0-4烷基）-R2或-（C0-4烷基）-R2，其中每个烷基组可能在链中还包括一个氧，但前提是在任何链杂原子之间至少有两个碳原子；R2代表：i）氢，C1-4全氟烷基，C2-3烯基，ii）苯基，萘基，5-或6-成员杂环芳基或1,2,3,4-四氢萘基，可选地被一到两个卤素，羟基，C1-4烷基，C1-4烷氧基取代，iii）C3-8环烷基，3-7成员杂环环烷基，iv）氨基，C1-4烷基氨基或双C1-4烷基氨基，但前提是在任何链杂原子之间至少有两个碳原子；以及其生理上可接受的盐，溶剂化物和制药组合物及其用于治疗与LDL-胆固醇循环水平升高相关的疾病。
• ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION
  申请人：GLAXO GROUP LIMITED

  公开号：EP1351937A1

  公开（公告）日：2003-10-15
• ARYL PIPERIDINE AND PIPERAZINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION
  申请人：GLAXO GROUP LIMITED

  公开号：EP1351936A1

  公开（公告）日：2003-10-15
• [EN] ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION<br/>[FR] DERIVES D'ARYLEPIPERIDINE UTILISES COMME INDUCTEURS D'EXPRESSION DE LDL
  申请人：GLAXO GROUP LTD

  公开号：WO2002055497A1

  公开（公告）日：2002-07-18

  The invention relates to a compound of formula (I), wherein Ar1 represents phenyl, naphthyl or phenyl fused by a C3-8cycloalkyl, where each group is optionally substituted by methylenedioxy or one or two groups independently represented by R1; Ar2 represents phenyl or a 5-6 membered heteroaromatic group, where each group is optionally substituted by one to four groups independently selected from halogen, C1-4 alkyl and C1-4 alkoxy; Ar3 represents a phenyl or a 5-6 membered heteroaromatic group, where each group is optionally substituted by one to four groups independently selected from hydroxy, alkyl, C1-4 alkoxy, C2-4 alkenyl, C2-4 alkenyloxy, C1-4 perfluoroalkoxy, C1-4 acylamino or an electron withdrawing group; A represents -C(H)-; E represents -C1-6 alkylene-; X represents -CON(H or C1-4alkyl)- or -N(H or C1-4alkyl)CO-; Y represents a direct link; R1 represents halogen, -S(C¿1-4? alkyl)-, -O-(C0-4 alkylene)-R?2¿ or -(C¿0-4?alkylene)-R?2¿, where each alkylene group may additionally incorporate an oxygen in the chain, with the proviso that there are at least two carbon atoms between any chain heteroatoms; R2 represents: i) hydrogen, C¿1-4? perfluoroalkyl, C2-3 alkenyl, ii) phenyl, naphthyl, a 5- or 6-membered heteroaromatic group or 1,2,3,4-tetrahydronaphthyl, optionally substituted by one or two halogen, hydroxy, C1-4 alkyl, C1-4 alkoxy groups, iii) C3-8cycloalkyl, a 3-7 membered heterocycloalkyl, iv) amino, C1-4 alkylamino or di-C1-4alkylamino, with the proviso that there are at least two carbon atoms between any chain heteroatoms; to salts, solvates and compositions thereof and their use in treating disorders associated with elevated levels of circulating LDL-cholesterol.